S2CID 43716740
The results of the trial were published in Annals of Internal Medicine on June 30
Last reviewed: June 15, 2026 Last updated: June 15, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
However, GLP-1 medications have longer lasting effects so these strategies will not have quite the same intensity or duration
When someone with a BMI of 35 and metabolic syndrome chooses resM over a conversation with their doctor about prescription GLP-1 options , they are potentially delaying effective treatment
Well, both Eli Lilly and Novo Nordisk have direct-to-consumer programs at around $500 per month, and theyre being utilized